CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
https://doi.org/10.17650/2222-1468-2014-0-2-46-50
Abstract
The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to significantly improve treatment outcomes.
The paper demonstrated two patients with the incurable of differentiated thyroid cancer resistant to therapy 131I. All patients received Nexavar (sorafenib). Its therapeutic effectiveness varied from partial response to long-term stabilization.About the Authors
P. A. Isaev
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
P. O. Rumyantsev
Endocrinology Research Center, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
V. V. Polkin
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
A. A. Ilyin
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
D. Yu. Syomin
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
T. A. Agababyan
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
S. V. Vasilkov
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
V. S. Medvedev
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
References
1. Sherman S.I. Target therapy of thyroid cancer. Biochem Pharmacol 2010 Sep;80(5):525–31.
2. Chougnet C., Brassard M., Leboulleux S. et al. Molecular targeted therapies for patient with refractory thyroid cancer. Clin Oncol (R Coll Radiol) 2010 Aug;22(6):448–55.
3. Licitra L., Locati L.D., Greco A. et al. Multikinase inhibitors in thyroid cancer. Eur J Cancer 2010 Apr;46(6): 1012–8.
4. Matuszczyk A., Petersenn S., Bockisch A. et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008 Mar;40(3):210–3.
5. Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014 Apr 23. doi: 10.1016/S0140– 6736(14) 60421–9.
6. Keefe S.M., Cohen M.A., Brose M.S. Targeting vascular endothelial growth factors receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res 2010 Feb 1;16(3):778–8.
Review
For citations:
Isaev P.A., Rumyantsev P.O., Polkin V.V., Ilyin A.A., Syomin D.Yu., Agababyan T.A., Vasilkov S.V., Medvedev V.S. CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I. Head and Neck Tumors (HNT). 2014;(2):46-50. (In Russ.) https://doi.org/10.17650/2222-1468-2014-0-2-46-50
Views:
818
Email this article 